A detailed history of Graham Capital Management, L.P. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 53,453 shares of XERS stock, worth $165,169. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,453
Previous 55,141 3.06%
Holding current value
$165,169
Previous $124,000 22.58%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.06 - $2.96 $3,477 - $4,996
-1,688 Reduced 3.06%
53,453 $152,000
Q2 2024

Aug 14, 2024

SELL
$1.7 - $2.45 $53,512 - $77,121
-31,478 Reduced 36.34%
55,141 $124,000
Q1 2024

May 15, 2024

BUY
$2.04 - $3.22 $101,663 - $160,468
49,835 Added 135.48%
86,619 $191,000
Q4 2023

Feb 14, 2024

SELL
$1.47 - $2.36 $30,318 - $48,675
-20,625 Reduced 35.93%
36,784 $86,000
Q3 2023

Nov 22, 2023

BUY
$1.8 - $2.69 $103,336 - $154,430
57,409 New
57,409 $106,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $420M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.